HemoBioTech, Inc. Featured in New Scientist Magazine

DALLAS--(BUSINESS WIRE)--Jan 16, 2008 - HemoBioTech (OTCBB: HMBT - News, http://www.hemobiotech.com), a developmental biopharmaceutical company focused on developing and commercializing the first viable human blood substitute, has been highlighted in the January 5-11th issue of New Scientist.

The article, "Fresh Hope For Emergency Blood Substitutes" concerns HemoBioTech's lead product, HemoTech, and describes the technology platform's potential ability to become a safe, inexpensive, oxygen-carrying human blood substitute. In the piece, Chief Executive Officer Dr. Arthur Bollon indicated that in an initial foreign clinical study where patients received HemoTech comprising 25% of their blood volume, the substitute made blood vessels dilate, showed no kidney toxicity, caused no inflammation and even stimulated production of new red blood cells. HemoTech, which induces red blood cell production, is designed to provide a blood replacement when otherwise unavailable and has been showing positive results.

"We are pleased to have national publications like New Scientist find both relevance and excitement in our emerging technology," said Dr. Bollon. "Our ability to isolate and nullify the source of toxicity that has plagued many companies' past attempts creates both a significant commercial and medical opportunity that, if approved, will be a great asset to the broad blood use market."

For further information on the article, visit the publication website at www.newscientist.com.

About New Scientist

New Scientist is a magazine publication that has been at the forefront of science and technology reporting since 1956. With New Scientist magazine, every week a comprehensive round-up of the latest science and technology news, reports, developments and research is distributed. Employing correspondents in every corner of the globe who contact leading scientists, New Scientist has the ability to scan thousands of journals and scientific websites to deliver the most up to date news to the public. Every issue provides the latest news across every field of science, features containing in-depth analysis and investigations of key scientific issues from our expert team of writers, the latest trends in emerging technologies and devices that could change the way we live and work, commentary, interviews, and job vacancies.

About HemoBioTech, Inc.

HemoBioTech is working on the development and commercialization of HemoTech, a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. HemoTech is composed of bovine hemoglobin that is chemically modified with adenosine triphosphate, adenosine, and glutathione. In addition to carrying oxygen through the bloodstream, HemoTech also induces erythropoiesis (red blood cell production). Based on preclinical studies and an initial foreign human clinical study, the company believes that HemoTech, due to its novel chemical composition, may significantly diminish or even eliminate the intrinsic toxicities that have plagued other attempts at developing blood substitutes. HemoTech is currently undergoing additional studies to confirm and possibly expand on these results. HemoTech is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, surgery, and other conditions. Corporate headquarters are located at 5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For further information visit our website at http://www.hemobiotech.com.

Safe Harbor Statement

Except for historical information, the matters discussed in this news release may be considered "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief, or current expectations of HemoBioTech and its management and are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a difference include, among others the successful pre-clinical development, the successful completion of clinical trials, the FDA review process and other governmental regulation, pharmaceutical collaborator interest and ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors which are included in HemoBioTech's Annual Report on Form 10-KSB for the year ended December 31, 2006, as amended, and HemoBioTech's other reports filed with the Securities and Exchange Commission.

Contact

HemoBioTech, Inc.
Arthur P. Bollon, PhD, 972-455-8950
Chief Executive Officer
abollon@hemobiotech.com
www.hemobiotech.com
or
Investor Relations:
The Investor Relations Group, Inc.
Christine Berni/Katie Nahnybida, 212-825-3210
cberni@investorrelationsgroup.com
knahnybida@investorrelationsgroup.com
or
Media:
Janet Vasquez/Michaela Heller, 212-825-3210
jvasquez@investorrelationsgroup.com
mheller@investorrelationsgroup.com

Posted: January 2008

View comments

Hide
(web2)